October 2022, The Enzyme Technology Alliance
Four European Biotech SMEs form the Enzyme Technology Alliance to offer protein and enzymatic process R&D from early discovery to chemical manufacturing across the entire value chain
The demand for sustainable yet scalable protein solutions is rising in the Pharmaceutical and Industrial Biotechnology sectors worldwide. The journey from a DNA or protein sequence to a valuable chemo-enzymatic process to deploy at scale requires broad expertise in R&D and manufacturing to bring such projects to success.
The newly formed Enzyme Technology Alliance allows start-ups and corporations globally to access the full scope of protein development to marketable products. Founders and members of the Enzyme Technology Alliance are the technologically complementary biotech-SMEs Candidum GmbH, Aminoverse B.V., ChiralVision B.V., and Enzymicals AG comprising 45 scientific experts and more than 150 years of combined experience ranging from enzyme discovery to facilitating cGMP enzymatic production of APIs.
December, 2019, Move into new and larger facilities
To keep up with the demand for production and R&D for immobilized enzymes ChiralVision has moved to a larger facility in the Delft area (Den Hoorn).
November 2019, MACBETH project
MACBETH is the acronym for "Membranes And Catalysts Beyond Economic and Technological Hurdles". The consortium of 24 partners provides a breakthrough technology of highly efficient catalytic membrane reactor (CMR) for advanced downstream processing by combining catalytic synthesis with the corresponding separation units in a single reactor. The revolutionary new reactor design will guarantee substantially smaller and safer production plants and thus reduce operational and investment costs.
PROJECT NR: GA 869896. CALL (PART) IDENTIFIER: H2020-NMBP-SPIRE-2019. PROJECT BUDGET: 20,7 M€
For more information please visit: www.macbeth-project.eu/
May 1, 2017, Expansion of dedicated production space (5 mt / y)
Production capacity for enzyme immobilization is expanded with a dedicated room with reactors of up to 200 liter allowing for an annual production of 5 metric tons of immobilized enzyme.
May 1, 2016, ERA-IB (Industrial Biotechnology) project “No P”
ChiralVision partners in the ERA-IB (Industrial Biotechnology) project “No P”. It entails the biotechnological application of enzymes for sugar coupling reactions.
October 1, 2016, Eurostars funding for biocide replacement (Bio-Attract)
Currently seeds are protected against pathogens with chemical protection. These agents will be phased out in the EU over the next years. Therefore a biobased seed dressing and soil application for increased production of crops is developed. Our invention attract local growth promoting organisms. In addition, enzymes are used to liberate nutrients from soil.
March 6, 2015, New SpinChem reactor increases performance of immobilized enzymes
ChiralVision has signed an agreement with Nordic Chemquest for the promotion of the "SpinChem" reactor that boosts the performance of heterogeneous catalysts like immobilized enzymes. SpinChem® is an innovative and unique concept invented by Nordic Chemquest for mass transfer enhancement in reactions involving solid phase reagents, encompassing several ways of using a stirring element to establish a forced flow through a heterogeneous reactant or catalyst bed, which is located inside the stirrer body.
February 17, 2014, Enzymatic phosphate recycling
ChiralVision partners in the EU funded project called "Phosfarm" which started in 2013. PhosFarm addresses the needs of an increasing market for economically and environmentally sustainable phosphorus (P) recovery from agricultural residues. The overall objective of the PhosFarm project is to develop a technology for the efficient recovery of phosphorus from agricultural residues, including a novel enzymatic process for the mineralisation of the organic phosphorus compounds into phosphates, which can be easily recovered by precipitation. In this way, the total phosphorus recovery will be increased by 30 to 80%. The result will be a semi-mobile on-site or a mobile trailer-mounted unit that can be operated stand-alone or easily integrated into already existing manure facilities or anaerobic digesters.
The research leading to results in this project receives funding from the European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement n°605771
January 1 2013, Immobilized CaLB with XL activity
Immobilized CaLB breaks activity records. With newly developed carriers and extra high enzyme loading extreme activities are obtained for maximum performance. Hydrolytic activity is 2.5x higher than the standard formulation and esterification power is 150% of NZ435 (Novozymes). Because the enzyme is covalently bound all reaction media are possible (from water, biphasic to pure organic solvent). Product number: IMMCALB-T2-150XL.
Technical product info and pricing
February 1, 2012 Clean water project (Endetech)
Pharmaceutical residues are emerging environmental contaminants that have been found in a wide range of environmental samples, including surface water, ground water, and drinking water. Polluting chemicals reach waters from various sources such as wastewater from urban areas, industrial installations or agriculture-related facilities such as animal husbandries.
Six partners from four different countries will work closely for this 3-year project: c-LEcta and the Goethe Frankfurt University (Germany), ChiralVision (The Netherlands), Da Volterra and the European Membrane Institute (France) and the Catalan Institute for Water Research (Spain).